文献速递心力衰竭与心肌病

门诊血流动力学监测与心力衰竭临床结局的关联:同期匹配队列分析

Association of Ambulatory Hemodynamic Monitoring of Heart Failure With Clinical Outcomes in a Concurrent Matched Cohort Analysis.
PubMed 文献 · JAMA Cardiol · 2019-01-01

该匹配队列研究基于Medicare索赔数据,纳入1087例植入肺动脉压力传感器的患者与1087例匹配对照。提示门诊血流动力学监测可能改善慢性心衰患者结局。

要点

  • 治疗组因心衰住院或死亡损失天数比例及全因住院或死亡损失天数比例均更低。
  • 门诊血流动力学监测可能改善真实世界慢性心衰患者长期结局。

核心结论

  • 植入肺动脉压力传感器的心衰患者较匹配对照心衰住院率更低,且存活且不在医院的时间更多。

研究设计与样本

  • 匹配队列研究,使用2014年6月1日至2016年3月31日Medicare索赔数据,纳入1087例植入肺动脉压力传感器患者与1087例匹配对照。

主要发现

  • 植入后12个月,治疗组发生616次心衰住院,对照组发生784次心衰住院。

临床怎么用

  • 对于慢性心衰患者,可考虑使用植入式肺动脉压力传感器指导门诊血流动力学监测以降低心衰住院风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In a randomized clinical trial, heart failure (HF) hospitalizations were lower in patients managed with guidance from an implantable pulmonary artery pressure sensor compared with usual care. It remains unclear if ambulatory monitoring could also improve long-term clinical outcomes in real-world practice. OBJECTIVE: To determine the association between ambulatory hemodynamic monitoring and rates of HF hospitalization at 12 months in clinical practice. DESIGN, SETTING, AND PARTICIPANTS: This matched cohort study of Medicare beneficiaries used claims data collected between June 1, 2014, and March 31, 2016. Medicare patients who received implants of a pulmonary artery pressure sensor were identified from the 100% Medicare claims database. Each patient who received an implant was matched to a control patient by demographic features, history of HF hospitalization, and number of all-cause hospitalizations. Propensity scoring based on comorbidities (arrhythmia, hypertension, diabetes, pulmonary disease, and renal disease) was used for additional matching. Data analysis was completed from July 2017 through January 2019. EXPOSURES: Implantable pulmonary artery pressure monitoring system. MAIN OUTCOMES AND MEASURES: The rates of HF hospitalization were compared using the Andersen-Gill method. Days lost owing to events were compared using a nonparametric bootstrap method. RESULTS: The study cohort consisted of 1087 patients who received an implantable pulmonary artery pressure sensors and 1087 matched control patients. The treatment and control cohorts were well matched by age (mean [SD], 72.7 [10.2] years vs 72.9 [10.1] years) and sex (381 of 1087 female patients [35.1%] in each group), medical history, comorbidities, and timing of preimplant HF hospitalization. At 12 months postimplant, 616 HF hospitalizations occurred in the treatment cohort compared with 784 HF hospitalizations in the control cohort. The rate of HF hospitalization was lower in the treatment cohort at 12 months postimplant (hazard ratio [HR], 0.76 [95% CI, 0.65-0.89]; P < .001). The percentage of days lost to HF hospitalizations or death were lower in the treatment group (HR, 0.73 [95% CI, 0.64-0.84]; P < .001) and the percentage of days lost owing to all-cause hospitalization or death were also lower (HR, 0.77 [95% CI, 0.68-0.88]; P < .001). CONCLUSIONS AND RELEVANCE: Patients with HF who were implanted with a pulmonary artery pressure sensor had lower rates of HF hospitalization than matched controls and spent more time alive out of hospital. Ambulatory hemodynamic monitoring may improve outcomes in patients with chronic HF.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Abraham J, Bharmi R, Jonsson O, et al. Association of Ambulatory Hemodynamic Monitoring of Heart Failure With Clinical Outcomes in a Concurrent Matched Cohort Analysis. JAMA Cardiol. 2019. PMID: 31090869. doi:10.1001/jamacardio.2019.1384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。